Genomic Health Inc (GHDX) - Product Pipeline Analysis, 2018 Update

  • ID: 4267327
  • Company Profile
  • 42 pages
  • GlobalData
  • Genomic Health Inc.
1 of 5

FEATURED COMPANIES

  • Hologic Inc
  • Myriad Genetics Inc
  • Novartis AG
  • Qiagen NV
  • Response Genetics Inc
  • Siemens AG
  • MORE
Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Genomic Health Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Hologic Inc
  • Myriad Genetics Inc
  • Novartis AG
  • Qiagen NV
  • Response Genetics Inc
  • Siemens AG
  • MORE
  • Genomic Health Inc Company Overview
  • Genomic Health Inc Company Snapshot
  • Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Genomic Health Inc - Pipeline Analysis Overview
  • Business Description
  • Genomic Health Inc - Key Facts
  • Genomic Health Inc - Major Products and Services
  • Genomic Health Inc Pipeline Products by Development Stage
  • Genomic Health Inc Pipeline Products Overview
  • Diagnostic Test - Non Small Cell Lung Cancer
  • Diagnostic Test - Non Small Cell Lung Cancer Product Overview
  • Liquid Biopsy-Based Bladder Cancer Test
  • Liquid Biopsy-Based Bladder Cancer Test Product Overview
  • Negative Biopsy Test - Prostate Cancer
  • Negative Biopsy Test - Prostate Cancer Product Overview
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay Product Overview
  • Oncotype Dx - Kidney Cancer
  • Oncotype Dx - Kidney Cancer Product Overview
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin Product Overview
  • Oncotype DX IVD Test
  • Oncotype DX IVD Test Product Overview
  • Oncotype SEQ - Breast Cancer Test
  • Oncotype SEQ - Breast Cancer Test Product Overview
  • Oncotype SEQ - Tissue Mutation Panel
  • Oncotype SEQ - Tissue Mutation Panel Product Overview
  • Oncotype TRACK
  • Oncotype TRACK Product Overview
  • Prognostic Test - Melanoma
  • Prognostic Test - Melanoma Product Overview
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma Product Overview
  • Genomic Health Inc - Key Competitors
  • Genomic Health Inc - Key Employees
  • Genomic Health Inc - Key Employee Biographies
  • Genomic Health Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Genomic Health Inc, Recent Developments
  • May 02, 2018: Genomic Health Reports First Quarter 2018 Financial Results
  • Apr 26, 2018: Large Independent Study Using the Oncotype DX Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
  • Mar 23, 2018: New Real-World Clinical Practice Data Reinforces the Value of the Oncotype DX Breast Recurrence Score Test for Patients, Physicians and the Health Care System
  • Mar 15, 2018: Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score Results of 11 to 25
  • Mar 08, 2018: Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook
  • Feb 26, 2018: Cesca Therapeutics Announces Commercial Launch Of AXP II System For Advanced Cord Blood Processing
  • Feb 26, 2018: Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX AR-V7 Nucleus Detect Test to Predict Treatment Response in Metastatic Disease
  • Feb 15, 2018: First comparison of common breast cancer tests finds varied accuracy of predictions
  • Feb 05, 2018: Oncotype DX Genomic Prostate Score Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care
  • Jan 08, 2018: Gene Test to Predict Breast Cancer Recurrence Less Cost Effective in Real World Practice
  • Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Genomic Health Inc Pipeline Products by Equipment Type
  • Genomic Health Inc Pipeline Products by Indication
  • Genomic Health Inc, Key Facts
  • Genomic Health Inc, Major Products and Services
  • Genomic Health Inc Number of Pipeline Products by Development Stage
  • Genomic Health Inc Pipeline Products Summary by Development Stage
  • Diagnostic Test - Non Small Cell Lung Cancer - Product Status
  • Diagnostic Test - Non Small Cell Lung Cancer - Product Description
  • Liquid Biopsy-Based Bladder Cancer Test - Product Status
  • Liquid Biopsy-Based Bladder Cancer Test - Product Description
  • Negative Biopsy Test - Prostate Cancer - Product Status
  • Negative Biopsy Test - Prostate Cancer - Product Description
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Status
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Description
  • Oncotype Dx - Kidney Cancer - Product Status
  • Oncotype Dx - Kidney Cancer - Product Description
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin - Product Status
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin - Product Description
  • Oncotype DX IVD Test - Product Status
  • Oncotype DX IVD Test - Product Description
  • Oncotype SEQ - Breast Cancer Test - Product Status
  • Oncotype SEQ - Breast Cancer Test - Product Description
  • Oncotype SEQ - Tissue Mutation Panel - Product Status
  • Oncotype SEQ - Tissue Mutation Panel - Product Description
  • Oncotype TRACK - Product Status
  • Oncotype TRACK - Product Description
  • Prognostic Test - Melanoma - Product Status
  • Prognostic Test - Melanoma - Product Description
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Status
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Description
  • Genomic Health Inc, Key Employees
  • Genomic Health Inc, Key Employee Biographies
  • Genomic Health Inc, Other Locations
  • Genomic Health Inc, Subsidiaries
  • Glossary
List of Figures
  • Genomic Health Inc Pipeline Products by Equipment Type
  • Genomic Health Inc Pipeline Products by Development Stage
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Siemens AG
  • Response Genetics Inc
  • Qiagen NV
  • Novartis AG
  • NanoString Technologies Inc
  • Myriad Genetics Inc
  • Hologic Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll